Posted inClinical Updates Wellness & Lifestyle
LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma
The LEAP-015 phase III trial found that adding lenvatinib and pembrolizumab to chemotherapy marginally improved progression-free survival but not overall survival in advanced gastroesophageal adenocarcinoma, with increased toxicity.